|
Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation |
Rogers G, Hoyle M, Thompson Coon J, Moxham T, Liu Z, Pitt M, Stein K |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Rogers G, Hoyle M, Thompson Coon J, Moxham T, Liu Z, Pitt M, Stein K. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation. Health Technology Assessment 2012; 16(22): 1-409 Authors' conclusions Study found dasatinib and nilotinib appear efficacious in terms of obtaining cytogenetic and haematological responses in both imatinib-resistant and imatinib-intolerant populations. Indexing Status Subject indexing assigned by CRD MeSH Antineoplastic Agents; Drug Resistance, Neoplasms; Leukemia, Myeloid; Piperazines; Pyrimidines; Thiazoles Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk AccessionNumber 32010000267 Date abstract record published 14/04/2010 |
|
|
|